Abstract:The COVID-19 disease is an ongoing global health concern. Although vaccination provides some protection, people are still susceptible to re-infection. Ostensibly, certain populations or clinical groups may be more vulnerable. Factors causing these differences are unclear and whilst socioeconomic and cultural differences are likely to be important, human genetic factors could influence susceptibility. Experimental studies indicate SARS-CoV-2 uses innate immune suppression as a strategy to speed-up entry and replication into the host cell. Therefore, it is necessary to understand the impact of variants in immunity-associated human proteins on susceptibility to COVID-19. In this work, we analysed missense coding variants in several SARS-CoV-2 proteins and their human protein interactors that could enhance binding affinity to SARS-CoV-2. We curated a dataset of 19 SARS-CoV-2: human protein 3D-complexes, from the experimentally determined structures in the Protein Data Bank and models built using AlphaFold2-multimer, and analysed the impact of missense variants occurring in the protein–protein interface region. We analysed 468 missense variants from human proteins and 212 variants from SARS-CoV-2 proteins and computationally predicted their impacts on binding affinities for the human viral protein complexes. We predicted a total of 26 affinity-enhancing variants from 13 human proteins implicated in increased binding affinity to SARS-CoV-2. These include key-immunity associated genes (TOMM70, ISG15, IFIH1, IFIT2, RPS3, PALS1, NUP98, AXL, ARF6, TRIMM, TRIM25) as well as important spike receptors (KREMEN1, AXL and ACE2). We report both common (e.g., Y13N in IFIH1) and rare variants in these proteins and discuss their likely structural and functional impact, using information on known and predicted functional sites. Potential mechanisms associated with immune suppression implicated by these variants are discussed. Occurrence of certain predicted affinity-enhancing variants should be monitored as they could lead to increased susceptibility and reduced immune response to SARS-CoV-2 infection in individuals/populations carrying them. Our analyses aid in understanding the potential impact of genetic variation in immunity-associated proteins on COVID-19 susceptibility and help guide drug-repurposing strategies.

The binding profile of SARS‐CoV‐2 with human leukocyte antigen polymorphisms reveals critical alleles involved in immune evasion

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape

Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants

Immune Evasion and ACE2 Binding Affinity Contribute to SARS-CoV-2 Evolution

Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies

HLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

Receptor binding mechanism and immune evasion capacity of SARS-CoV-2 BQ.1.1 lineage

Immune Evasion of Neutralizing Antibodies by SARS-CoV-2 Omicron.

Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants

Molecular basis of receptor binding and antibody neutralization of Omicron

Underlying driving forces of the SARS-CoV-2 evolution: immune evasion and ACE2 binding affinity

Molecular Insights into Striking Antibody Evasion of SARS-CoV-2 Omicron Variant

Altered spike dynamics drives immune evasion of SARS-CoV-2

Structural insights into immune escape at killer T cell epitope by SARS-CoV-2 Spike Y453F variants

Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations

Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion

Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics

Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans